Samsung Biologics Q3 revenue rises 19% to 1.49 trillion won

Samsung Biologics reported Q3 2026 revenue of 1.49 trillion won and operating profit of 640.1 billion won, up 19% and 1% year over year. The company raised its full-year revenue growth guidance from 15–20% to 20%, citing full utilization of Plants 1–4, the ramp-up of Plant 5 and revenue from the Rockville facility acquired in March.

• Q3 revenue reached 1.49 trillion won, operating profit 640.1 billion won
• Full-year revenue growth guidance raised from 15–20% to 20%
• Cumulative orders hit $22 billion across 117 CMO and 184 CDO deals
• Tender for PolyPeptide Group secured 87.88% of shares vs 66.7% threshold